Jefferies analyst Michael Yee raised the price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $75.00) while maintaining a Buy rating.

The analyst commented, "We continue to like GILD as an under owned, inexpensive (trades at 10x) turnaround story and see 2021 as a trough year with drivers and catalysts for growing revenue and EPSfrom here. Sentiment continues to improve and investors should have more confidence on forward growth when 3 catalysts occur this year: Phase III Trodelvy HR+ breast cancer data H2, Phase II lung cancer data H2, and HIV long-acting pill combo visibility (YE).TIGIT remains a call option."